Composite primary end points in cardiovascular outcomes trials involving type 2 diabetes patients: Should unstable angina be included in the primary end point?

Nikolaus Marx, Darren K McGuire, Vlado Perkovic, Hans Juergen Woerle, Uli C. Broedl, Maximilian Von Eynatten, Jyothis T. George, Julio Rosenstock

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Reductions in cardiovascular (CV) outcomes in recently reported trials, along with the recent approval by the U.S. Food and Drug Administration of an additional indication for empagliflozin to reduce the risk of CV death in type 2 diabetes patientswith evidence of CV disease, have renewed interest in CV outcome trials (CVOTs) of glucoselowering drugs. Composite end points are a pragmatic necessity in CVOTs to ensure that sample size and duration of follow-up remain reasonable. Combining clinical outcomes into a composite end point increases the numbers of events ascertained and thus statistical power and precision. Historically, composite CV end points in diabetes trials have included a largernumber of components,while more recent CVOTs almost exclusively use a composite of CV death, nonfatal myocardial infarction (MI), and nonfatal strokedthe so-called three-point major adverse CV event (3P-MACE) compositedor add hospitalization for unstable angina (HUA) to these three outcomes (4P-MACE). The inclusion of HUA increases the number of events for analysis, but noteworthy disadvantages include clinical subjectivity in ascertainment of HUA and its lower prognostic relevance compared with CV death, MI, or stroke. Furthermore, results from recent CVOTs indicate that glucose-lowering agents seem to have minimal impact on HUA. Its inclusion therefore potentially favors a shift of the hazard ratio (HR) toward the null, which is especially problematic in trials designed to demonstrate noninferiority. The primary outcome of 3P-MACEmay offer a better balance than 4P-MACE between statistical efficiency, operational complexity, the likelihood of diagnostic precision (and therefore clinical relevance) for each of the component outcomes, clinical importance, and the aim to adequately capture any potential treatment effect of the intervention. Nevertheless, as individual medications may mechanistically differ in their impact on CV outcomes, no particular individual or composite end point can be seen as a "gold standard" for CVOTs of all glucoselowering drugs.

Original languageEnglish (US)
Pages (from-to)1144-1151
Number of pages8
JournalDiabetes Care
Volume40
Issue number9
DOIs
StatePublished - Sep 1 2017

Fingerprint

Unstable Angina
Type 2 Diabetes Mellitus
Hospitalization
Myocardial Infarction
United States Food and Drug Administration
Pharmaceutical Preparations
Sample Size
Cardiovascular Diseases
Stroke
Glucose
Therapeutics

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialized Nursing

Cite this

Composite primary end points in cardiovascular outcomes trials involving type 2 diabetes patients : Should unstable angina be included in the primary end point? / Marx, Nikolaus; McGuire, Darren K; Perkovic, Vlado; Woerle, Hans Juergen; Broedl, Uli C.; Von Eynatten, Maximilian; George, Jyothis T.; Rosenstock, Julio.

In: Diabetes Care, Vol. 40, No. 9, 01.09.2017, p. 1144-1151.

Research output: Contribution to journalArticle

Marx, Nikolaus ; McGuire, Darren K ; Perkovic, Vlado ; Woerle, Hans Juergen ; Broedl, Uli C. ; Von Eynatten, Maximilian ; George, Jyothis T. ; Rosenstock, Julio. / Composite primary end points in cardiovascular outcomes trials involving type 2 diabetes patients : Should unstable angina be included in the primary end point?. In: Diabetes Care. 2017 ; Vol. 40, No. 9. pp. 1144-1151.
@article{89d4628fbb154e48b8f10f6e3d419a19,
title = "Composite primary end points in cardiovascular outcomes trials involving type 2 diabetes patients: Should unstable angina be included in the primary end point?",
abstract = "Reductions in cardiovascular (CV) outcomes in recently reported trials, along with the recent approval by the U.S. Food and Drug Administration of an additional indication for empagliflozin to reduce the risk of CV death in type 2 diabetes patientswith evidence of CV disease, have renewed interest in CV outcome trials (CVOTs) of glucoselowering drugs. Composite end points are a pragmatic necessity in CVOTs to ensure that sample size and duration of follow-up remain reasonable. Combining clinical outcomes into a composite end point increases the numbers of events ascertained and thus statistical power and precision. Historically, composite CV end points in diabetes trials have included a largernumber of components,while more recent CVOTs almost exclusively use a composite of CV death, nonfatal myocardial infarction (MI), and nonfatal strokedthe so-called three-point major adverse CV event (3P-MACE) compositedor add hospitalization for unstable angina (HUA) to these three outcomes (4P-MACE). The inclusion of HUA increases the number of events for analysis, but noteworthy disadvantages include clinical subjectivity in ascertainment of HUA and its lower prognostic relevance compared with CV death, MI, or stroke. Furthermore, results from recent CVOTs indicate that glucose-lowering agents seem to have minimal impact on HUA. Its inclusion therefore potentially favors a shift of the hazard ratio (HR) toward the null, which is especially problematic in trials designed to demonstrate noninferiority. The primary outcome of 3P-MACEmay offer a better balance than 4P-MACE between statistical efficiency, operational complexity, the likelihood of diagnostic precision (and therefore clinical relevance) for each of the component outcomes, clinical importance, and the aim to adequately capture any potential treatment effect of the intervention. Nevertheless, as individual medications may mechanistically differ in their impact on CV outcomes, no particular individual or composite end point can be seen as a {"}gold standard{"} for CVOTs of all glucoselowering drugs.",
author = "Nikolaus Marx and McGuire, {Darren K} and Vlado Perkovic and Woerle, {Hans Juergen} and Broedl, {Uli C.} and {Von Eynatten}, Maximilian and George, {Jyothis T.} and Julio Rosenstock",
year = "2017",
month = "9",
day = "1",
doi = "10.2337/dc17-0068",
language = "English (US)",
volume = "40",
pages = "1144--1151",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "9",

}

TY - JOUR

T1 - Composite primary end points in cardiovascular outcomes trials involving type 2 diabetes patients

T2 - Should unstable angina be included in the primary end point?

AU - Marx, Nikolaus

AU - McGuire, Darren K

AU - Perkovic, Vlado

AU - Woerle, Hans Juergen

AU - Broedl, Uli C.

AU - Von Eynatten, Maximilian

AU - George, Jyothis T.

AU - Rosenstock, Julio

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Reductions in cardiovascular (CV) outcomes in recently reported trials, along with the recent approval by the U.S. Food and Drug Administration of an additional indication for empagliflozin to reduce the risk of CV death in type 2 diabetes patientswith evidence of CV disease, have renewed interest in CV outcome trials (CVOTs) of glucoselowering drugs. Composite end points are a pragmatic necessity in CVOTs to ensure that sample size and duration of follow-up remain reasonable. Combining clinical outcomes into a composite end point increases the numbers of events ascertained and thus statistical power and precision. Historically, composite CV end points in diabetes trials have included a largernumber of components,while more recent CVOTs almost exclusively use a composite of CV death, nonfatal myocardial infarction (MI), and nonfatal strokedthe so-called three-point major adverse CV event (3P-MACE) compositedor add hospitalization for unstable angina (HUA) to these three outcomes (4P-MACE). The inclusion of HUA increases the number of events for analysis, but noteworthy disadvantages include clinical subjectivity in ascertainment of HUA and its lower prognostic relevance compared with CV death, MI, or stroke. Furthermore, results from recent CVOTs indicate that glucose-lowering agents seem to have minimal impact on HUA. Its inclusion therefore potentially favors a shift of the hazard ratio (HR) toward the null, which is especially problematic in trials designed to demonstrate noninferiority. The primary outcome of 3P-MACEmay offer a better balance than 4P-MACE between statistical efficiency, operational complexity, the likelihood of diagnostic precision (and therefore clinical relevance) for each of the component outcomes, clinical importance, and the aim to adequately capture any potential treatment effect of the intervention. Nevertheless, as individual medications may mechanistically differ in their impact on CV outcomes, no particular individual or composite end point can be seen as a "gold standard" for CVOTs of all glucoselowering drugs.

AB - Reductions in cardiovascular (CV) outcomes in recently reported trials, along with the recent approval by the U.S. Food and Drug Administration of an additional indication for empagliflozin to reduce the risk of CV death in type 2 diabetes patientswith evidence of CV disease, have renewed interest in CV outcome trials (CVOTs) of glucoselowering drugs. Composite end points are a pragmatic necessity in CVOTs to ensure that sample size and duration of follow-up remain reasonable. Combining clinical outcomes into a composite end point increases the numbers of events ascertained and thus statistical power and precision. Historically, composite CV end points in diabetes trials have included a largernumber of components,while more recent CVOTs almost exclusively use a composite of CV death, nonfatal myocardial infarction (MI), and nonfatal strokedthe so-called three-point major adverse CV event (3P-MACE) compositedor add hospitalization for unstable angina (HUA) to these three outcomes (4P-MACE). The inclusion of HUA increases the number of events for analysis, but noteworthy disadvantages include clinical subjectivity in ascertainment of HUA and its lower prognostic relevance compared with CV death, MI, or stroke. Furthermore, results from recent CVOTs indicate that glucose-lowering agents seem to have minimal impact on HUA. Its inclusion therefore potentially favors a shift of the hazard ratio (HR) toward the null, which is especially problematic in trials designed to demonstrate noninferiority. The primary outcome of 3P-MACEmay offer a better balance than 4P-MACE between statistical efficiency, operational complexity, the likelihood of diagnostic precision (and therefore clinical relevance) for each of the component outcomes, clinical importance, and the aim to adequately capture any potential treatment effect of the intervention. Nevertheless, as individual medications may mechanistically differ in their impact on CV outcomes, no particular individual or composite end point can be seen as a "gold standard" for CVOTs of all glucoselowering drugs.

UR - http://www.scopus.com/inward/record.url?scp=85028091172&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028091172&partnerID=8YFLogxK

U2 - 10.2337/dc17-0068

DO - 10.2337/dc17-0068

M3 - Article

C2 - 28830955

AN - SCOPUS:85028091172

VL - 40

SP - 1144

EP - 1151

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 9

ER -